PrimeBodyMind is the journal of the fastest-growing category in medicine — the doctors leading it, the science underneath it, and the wealth being created by the people who showed up early with standards. Best practices from the field, documented since 2024.
Eli Lilly market value — the first drugmaker in history to cross a trillion, powered by GLP-1s
Eli Lilly investor relationsProjected GLP-1 market by 2030 — J.P. Morgan global research forecast
J.P. Morgan Global ResearchProjected medspa market by 2033, from $21B in 2024 — a 16% annual growth curve
American Med Spa AssociationXPRIZE Healthspan — the largest health prize in history, now in clinical trials with ten finalist teams
XPRIZE HealthspanThis is not a trend chart. It is a wealth-creation record — capital, clinics, and compounds moving in the same direction at the same time. The posts below document how it happened, and what the people winning are doing about it.
The wild-west phase is ending. The consumer peptide channels are being banned and raided; the FTC and FDA are circling the gray market; and what replaces it is wholesale-only B2B infrastructure — 503A/503B sourcing networks, physician oversight, integrated financing, and one login for the entire practice economy.
Read the article
XPRIZE Healthspan — the largest health prize in history at $101 million — named its ten finalist teams, each awarded $1 million to test real therapies that restore muscle, cognitive, and immune function in people over 65.
Read the article
Dr. Gabrielle Lyon's muscle-centric medicine went mainstream with Forever Strong, and the clinical consensus moved with it: lean mass is the organ of longevity — the thing that protects against the falls, the frailty, and the glucose curves that end healthspans early.
Read the article
Bryan Johnson's Blueprint raised $60 million to turn a personal longevity protocol into a product company — a watershed moment for the category.
Read the article
The longevity clinic stopped being a concept and became a membership business. The medspa market — $21 billion in 2024, projected toward $78 billion by 2033 — began consolidating around recurring protocol plans.
Read the article
Dr. Peter Attia's Outlive became the category's defining book, and The Drive podcast became its faculty lounge. The result in clinics across the country: patients now arrive educated, asking for protocols by name.
Read the article
Telehealth made cash-pay medicine normal, and the medspa boom followed — U.S. medspas nearly doubled since 2018, on a trajectory toward 12,000+ locations.
Read the article
Eli Lilly became the first pharmaceutical company in history to cross $1 trillion in market value, powered by GLP-1 drugs. Wall Street's answer was fast: J.P. Morgan projected the incretin market at $200 billion by 2030.
Read the articleFrom TED stages to the most-cited podcasts in medicine, these are the clinicians and scientists whose work built the category the market is now funding. Start anywhere — their lectures, books, and interviews are the curriculum.
The category's translator. His TED talks and The Drive podcast moved longevity from the lab to the living room — and "Medicine 3.0" into practice economics.
His TED talk on why we age remains one of the most-watched in the field. The sirtuin and information-theory work behind half the NAD+ industry.
Brought the mind discipline to millions — sleep, light, dopamine, protocol-driven behavior. Proof the category is neurology as much as endocrinology.
Made food-as-medicine a working clinic model and a bestseller shelf. The bridge from traditional practice to longevity practice design.
Turned fasting science into a clinical protocol used in practices worldwide — the model for a measured, sellable, repeatable program.
Leading the scientific case that aging itself is a treatable condition — the trial the FDA world is watching.
Made lean mass the clinical priority of the category — and gave practices the protocol with the best adherence in the field.
Made longevity investable at planetary scale — the $101M Healthspan prize and the longevity-clinic chain model.
Not a physician — the civilian who made protocols a headline, a movement, and then a $60M company. The demand curve, personified.
Eli Lilly's climb past $1 trillion in market value on GLP-1s, with Novo Nordisk beside it as Europe's most valuable company — the fastest wealth creation in pharmaceutical history, built on the same category of medicine practices prescribe every day.
The medspa and longevity-clinic economy is compounding at roughly 16% a year. The winners are ordinary practice owners who added recurring protocol revenue — GLP-1 management, peptide programs, hormones — to rooms they already owned.
The newest layer: professionals who represent platforms to practices — corporate pharmacy sales pros, entrepreneurs, and fitness coaches earning recurring revenue for the life of every account they open. The same B2B wealth model that built every great distribution industry, arriving in longevity.
Protocols as memberships, not injections as transactions. Recurring revenue is the entire model.
They arrive holding a podcast. Answer it with clinical precision or lose them to someone who will.
A high-ticket plan without financing at the point of decision is a plan that dies in the follow-up call.
503A/503B sourcing networks exist so practices stop paying retail and start compounding margin.
Fragmented software is the silent tax on every practice that hasn't consolidated.
The gray market is being banned; the compliance-first practice economy is being built. One of them has a future.
XPRIZE therapies, GLP-1 expansion, and clinic consolidation are all moving in one direction. Early with standards beats late with budget.
I've spent my career building sales organizations and healthcare commerce infrastructure — turning fast-growing categories into systems that work on a Tuesday morning, not just in a pitch deck. I don't claim to be the smartest person in longevity. I've simply been in enough emerging markets to know what an organized one looks like when it arrives, and this is that.
PrimeBodyMind is my running record of it: the doctors worth reading, the numbers worth trusting, the practices worth copying, and the wealth being created — honestly, transparently, and mostly by unglamorous people who showed up early and did the work. If it helps you see the category more clearly, it has done its job.
One life. This is it. Build accordingly.
Founder, PrimeBodyRX · primebodyrx.com · September 2026
Serious reading for people who take the long view — metabolic science, disciplined eating, training that ages well, and the alignment everything else sits on. No fluff, no fads, no filler.
GLP-1 management, peptide programs, and clinic economics compounding at double digits — what it means for practice owners positioned correctly.
In preparation
Three threads worth a clinician's attention: metabolic maintenance, recovery consistency, and overnight glucose stability.
In preparation
Protein first, electrolytes serious, a measured 30-day run, and an exit strategy. Ketogenic eating as a discipline — not a personality.
In preparation
What the evidence supports, what it doesn't, and who the approach actually serves. No cheering, no sneering.
In preparation
Glycemic control is the most underrated longevity lever — and the easiest to implement badly. Here's the adult version.
In preparation
Three plates in fifteen minutes each — breakfast, lunch, dinner — with macros noted and no recipe worth forgetting.
In preparation
One ninety-minute Sunday session, a 2-2-1 framework, four recipes. Six days of clean keto eating for people with actual jobs.
In preparation
Crow pose, loaded holds, breath discipline, joint longevity. Yoga as strength training for a hundred-year body.
In preparation
Load management, the zone 2 balance, and why the barbell matters more at 60 than at 25.
In preparation
Sleep, mobility, active rest — the session your numbers recover with. Skip it twice and you'll stop skipping it.
In preparation
Posture, breath, spine, and nervous-system regulation — the literal foundation everything else sits on.
In preparation
Breath, mobility, light, stillness. Twenty minutes a day that pair with every protocol above.
In preparation
The Daily Demo shows the sourcing, clinical review and financing these pages document. Tell us where to reach you.